Plate III · The pharmacokinetic record
BPC-157 and TB-500 Half-Life and Research Pharmacokinetics
What the animal pharmacokinetic studies measured for each constituent — a short elimination half-life on one side, dose-proportional human data for a parent protein on the other — and why the blend itself has no validated profile.
BPC-157 and TB-500 half-life: what the studies measured
The BPC-157 TB-500 half-life question has no single answer, because the blend has no validated pharmacokinetic profile of its own — and the two constituents behave very differently in the studies that exist.
For BPC-157, the first formal PK/ADME characterization, in rats and beagle dogs, reported linear pharmacokinetics and a very short elimination half-life of under 30 minutes, with intramuscular bioavailability around 14-19% in rats and 45-51% in dogs, and rapid breakdown into small peptide fragments entering normal amino-acid metabolism [5]. A sub-30-minute elimination half-life is the central pharmacokinetic fact about the BPC-157 leg, and it is an animal figure, not a human one.
For the TB-500 leg, no specific half-life is established for the Ac-LKKTETQ heptapeptide. The human pharmacokinetic data on record are for full-length thymosin beta-4: intravenous Tbeta4 showed dose-proportional pharmacokinetics across 40 healthy volunteers to 1,260 mg [6], and a 2021 first-in-human study of recombinant Tbeta4 in 84 volunteers reported dose-proportional pharmacokinetics with no accumulation [7]. Those are the parent protein, not the marketed fragment — which is exactly why no validated half-life for "TB-500" can be quoted.
What Is the Half-Life of BPC-157 and TB-500?
BPC-157's elimination half-life was reported under 30 minutes in a rat and beagle-dog PK study [5]. No validated human half-life exists for either constituent at research doses, and none for the blend. Human full-length thymosin beta-4 showed dose-proportional pharmacokinetics [6][7], but no specific half-life is established for the TB-500 heptapeptide.
Why a short half-life shapes the research picture
A sub-30-minute elimination half-life is a strong constraint on how a molecule could behave in a living system [5]. It is the kind of figure that, in a developed drug, would drive frequency and route decisions — and its absence for the fragment and for the blend is why community dosing schedules have no pharmacokinetic anchor.
The modest, route- and species-dependent intramuscular bioavailability reported for BPC-157 (roughly 14-19% in rats, 45-51% in dogs) reinforces the point [5]. These are properties of one constituent measured in two species; they do not transfer to the seven-residue fragment, and they say nothing about how a co-administered pairing distributes or clears. The blend's pharmacokinetics are simply uncharacterized, and no figure on this page should be read as describing the pairing.
How Often Should BPC-157 and TB-500 Be Administered in Research?
There is no validated dose or frequency for the blend. The underlying rodent studies used intraperitoneal dosing schedules specific to each model [1][4]; community "loading then maintenance" blend protocols have no controlled-trial basis. Frequency claims circulating online are not grounded in the published pharmacokinetic record [5].
BPC 157 TB 500 Oral vs Injectable in Research Routes
Searches for "bpc 157 tb 500 oral" run into a thin record. BPC-157 is studied as a "stable gastric" peptide, which is why oral and peroral routes appear in its literature at all [5]. Oral blend products are marketed, but they lack validated pharmacokinetics — the oral behavior of the pairing has not been characterized [4].
The predominant research-community routes for the blend are subcutaneous and intramuscular, while the underlying efficacy studies for both peptides were largely intraperitoneal in rodents [1][4]. Intravenous appears in the human Phase 1 work on full-length Tbeta4 [6][7] and a BPC-157 IV safety pilot [11]. None of these routes is supported by a controlled human efficacy trial of the combination.
Can BPC-157 and TB-500 Be Taken Orally Instead of Injected?
BPC-157 is studied as a "stable gastric" peptide, and oral blend products are marketed, but they lack validated pharmacokinetics [5]. Predominant research-community routes are subcutaneous and intramuscular; the underlying efficacy studies for both peptides were largely intraperitoneal [1][4]. Oral pharmacokinetics for the pairing have not been established.
How Do You Reconstitute a BPC-157 / TB-500 Blend?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated [4]. A frequent practical caveat sits underneath that simple description: product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated "Wolverine" material are not guaranteed, which compounds the existing fragment-versus-full-protein caveat around TB-500 [4]. What follows is research handling, not a preparation instruction for use.
How Do You Reconstitute a BPC-157 / TB-500 Blend (10mg)?
Both constituents are supplied as lyophilized powders for research use and are reconstituted in bacteriostatic or sterile water and refrigerated [4]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed; this describes research handling only, not human-use guidance.
Can BPC-157 and TB-500 Be Mixed in One Syringe?
A common research-community practice is to reconstitute the two peptides separately or in a shared vial, but no controlled study validates a co-formulation, ratio, or combined dose [4]. Identity and purity of unregulated "Wolverine" material are unverified outside formal studies. Whether the two are co-housed is a handling question; the combination's pharmacology remains unstudied.